Catalog No.
Product Name
Application
Product Information
Citations
-
PDE4 Inhibitor
Revamilast is an orally active phosphodiesterase-4 (PDE4) inhibitor with a reported IC50 of 3 nM. This compound effectively inhibits the production of tumor necrosis factor-alpha (TNF-α), making it a valuable tool for research into inflammatory conditions. Applications include studies related to rheumatoid arthritis, plaque psoriasis, asthma, and other related inflammatory diseases. -
PDE4 Inhibitor
PDE4-IN-15 is a selective inhibitor of phosphodiesterase 4 (PDE4) with an IC50 value of 0.17 μM. This compound demonstrates notable anti-TNF-α activity, exhibiting an EC50 of 0.19 μM, which is significant for inflammatory research. Additionally, PDE4-IN-15 shows good skin permeability, making it suitable for studies involving topical administration and localized therapeutic applications. -
PDE Inhibitor
Theophylline sodium glycinate is a potent phosphodiesterase (PDE) inhibitor with significant effects on airway smooth muscle relaxation. It acts primarily by inhibiting PDE3, which contributes to its anti-inflammatory properties through the upregulation of IL-10 and the inhibition of NF-κB translocation into the nucleus. Additionally, Theophylline sodium glycinate has been shown to induce apoptosis. This reagent is valuable for research applications related to asthma and chronic obstructive pulmonary disease (COPD). -
Anti-inflammatory/Anti-tumor/Anti-mite Agent
2′-Hydroxy-5′-methoxyacetophenone is an acetophenone derivative that modulates inflammatory responses primarily through inhibition of the NF-κB signaling pathway. This compound demonstrates significant anti-tumor properties, particularly against ovarian cancer, and exhibits acaricidal activity. Additionally, it effectively inhibits enzymes such as α-amylase, collagenase, and aldose reductase with IC50 values of 0.928 μM, 3.264 μM, and 20.046 μM, respectively, indicating its potential in diabetes research. -
PDE-4 Inhibitor
Apremilast-d5 is a deuterated analog of Apremilast, a potent inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC50 of 74 nM. This compound effectively reduces TNF-α release in response to lipopolysaccharide (LPS) stimulation, exhibiting an IC50 of 104 nM. Apremilast-d5 is valuable for research applications related to inflammatory diseases and the modulation of immune responses. -
Phosphodiesterase (PDE) Inhibitor
CDC801 is a potent inhibitor of phosphodiesterase 4 (PDE4) and tumor necrosis factor-α (TNF-α), with IC50 values of 1.1 μM and 2.5 μM, respectively. This compound exhibits significant anti-inflammatory activity, making it a valuable tool for research into conditions associated with elevated TNF-α levels, such as autoimmune diseases and chronic inflammatory disorders. CDC801 is suitable for exploring the therapeutic potential of PDE4 inhibition and its effects on inflammatory pathways. -
PDE Inhibitor
Theophylline monohydrate is a potent phosphodiesterase (PDE) inhibitor that primarily targets PDE3, promoting relaxation of airway smooth muscle. This compound exhibits anti-inflammatory properties by increasing interleukin-10 (IL-10) levels and inhibiting the nuclear translocation of NF-κB. Additionally, Theophylline monohydrate is known to induce apoptosis in certain cell types. It is widely utilized in research related to asthma and chronic obstructive pulmonary disease (COPD). -
Chloride Channel Inhibitor
Shikonin is a potent inhibitor of the TMEM16A chloride channel, exhibiting an IC50 value of 6.5 μM. This compound functions as a specific inhibitor of pyruvate kinase M2 (PKM2) and also modulates inflammatory pathways by inhibiting TNF-α and NF-κB activation. In addition, Shikonin decreases exosome secretion by impairing glycolytic processes and effectively inhibits AIM2 inflammasome activation. Its diverse activities make it a valuable reagent for investigating cellular signaling and inflammatory responses in research applications. -
Endogenous Metabolite
Taurohyodeoxycholic acid, an endogenous metabolite and 6 alpha-hydroxylated bile acid, exhibits anti-inflammatory properties by significantly reducing colonic myeloperoxidase (MPO) activity, TNF-α, IL-6 serum levels, and COX-2 expression. It has been shown to alleviate ulcerative colitis induced by trinitrobenzene sulfonic acid by modulating the balance between Th1/Th2 and Th17/Treg cells. Additionally, taurohyodeoxycholic acid improves outcomes in high-fat diet-induced nonalcoholic fatty liver disease in murine models and protects against hepatotoxicity in bile fistula rats. This compound is valuable for research into nonalcoholic fatty liver disease (NAFLD), colitis, and biliary fistula conditions. -
Amylase Substrate
Maltotetraose is a carbohydrate compound that serves as a substrate for enzyme-linked assays to measure amylase activity in biological fluids. Its primary biological activity includes the reduction of TNF-α-induced inflammatory responses through inhibition of NF-κB activity and decreased expression of ICAM-1. Additionally, maltotetraose inhibits PDGF-induced vascular smooth muscle cell migration and neovascularization. Its derivatives can also be utilized as probes for detecting bacterial infections by targeting the maltodextrin transporter, making maltotetraose a valuable tool in research related to atherosclerosis and inflammatory diseases. -
Endogenous Metabolite
Lacto-N-neotetraose (LNnT) is an endogenous metabolite that plays a crucial role in modulating inflammation. It has been shown to inhibit TNF-α-induced IL-8 secretion in immature epithelial cells, highlighting its anti-inflammatory properties. LNnT is of particular interest in wound healing research, as it demonstrates the potential to enhance wound closure processes. -
Endogenous Metabolite
D-chiro-Inositol is an endogenous metabolite that plays a significant role in glucose metabolism and insulin signaling. It is known to improve insulin sensitivity, reduce hyperglycemia and serum androgen levels, and alleviate metabolic disturbances associated with conditions such as type 2 diabetes and polycystic ovary syndrome. D-chiro-Inositol also demonstrates anti-inflammatory properties by reducing pro-inflammatory factors and cytokines, making it relevant in research on liver cirrhosis and breast cancer. Its multifaceted biological activities render it a valuable reagent for studies focusing on metabolic health and related disorders. -
MAO-A/B Inhibitor
1,4-Naphthoquinone serves as a potent inhibitor targeting monoamine oxidase A and B (MAO-A/B) with competitive inhibition of MAO-B (Ki=1.4 μM) and non-competitive inhibition of MAO-A (Ki=7.7 μM). This compound exhibits broad-spectrum biological activity, inhibiting various DNA polymerases alongside notable anti-tumor, anti-inflammatory, and antibacterial properties. Its mechanism includes the induction of oxidative stress, glutathione (GSH) depletion, suppression of DNA synthesis, and blockage of NF-κB nuclear translocation. 1,4-Naphthoquinone is applicable in research involving melanoma and colon cancer cell growth, endothelial cell function, and models of lipopolysaccharide (LPS)-induced inflammation. -
PPARγ Agonist
Rosiglitazone hydrochloride is a selective agonist of the peroxisome proliferator-activated receptor gamma (PPARγ), demonstrating an EC50 of 60 nM and a Kd of 40 nM. In addition to its primary action, it acts as a TRPC5 activator with an EC50 of 30 μM and a TRPM3 inhibitor. This compound is extensively utilized in research related to obesity, diabetes, cellular senescence, and ovarian cancer. -
HDAC/NAMPT Inhibitor
HDAC/NAMPT-IN-1 is a potent dual inhibitor of histone deacetylases (HDAC) and nicotinamide adenine dinucleotide (NAD+) biosynthesis enzyme NAMPT, exhibiting IC50 values ranging from 0.72 to 37081 nM for HDAC and 1618 nM for NAMPT. This compound demonstrates significant potential in modulating cellular acetylation levels and metabolic processes associated with cancer and neurodegenerative diseases. Its application in research can facilitate studies on epigenetic regulation and NAD+ metabolism, contributing to a deeper understanding of cellular mechanisms and therapeutic strategies. -
CYP51/HDAC Inhibitor
CYP51/HDAC-IN-1 is a potent dual inhibitor of CYP51 and HDAC, demonstrating significant biological activity in combating virulence factors as well as down-regulating resistance-associated genes. This compound shows promising therapeutic potential for treating tropical candidiasis and cryptococcal meningitis, making it a valuable tool for research in antifungal therapies. -
HDAC1/MAO-B Inhibitor
HDAC1/MAO-B-IN-1 is a selective inhibitor targeting both HDAC1 and MAO-B, exhibiting IC50 values of 21.4 nM and 99.0 nM, respectively. This compound effectively crosses the blood-brain barrier, making it a valuable tool for studying neurological disorders. Its potential applications include research into Alzheimer's disease and related pathologies, facilitating the exploration of epigenetic modifications and monoamine metabolism in the brain. -
Dual HDAC/HSP90 Inhibitor
HDAC/HSP90-IN-1 is a potent dual inhibitor targeting both histone deacetylases (HDAC) with an IC50 of 194 nM and heat shock protein 90 (HSP90), specifically HSP90α with an IC50 of 153 nM. This compound induces the expression of HSP70, downregulates HSP90 client proteins, and facilitates the acetylation of α-tubulin and histone H3 in cancer cells. Additionally, HDAC/HSP90-IN-1 effectively reduces PD-L1 expression in interferon-gamma treated H1975 cells, making it a valuable tool for cancer research, particularly in lung and colon malignancies. -
sEH/HDAC6 inhibitor
sEH/HDAC6-IN-1 is a selective, orally active dual inhibitor of soluble epoxide hydrolase (sEH) and histone deacetylase 6 (HDAC6), exhibiting IC50 values of 2 nM for human sEH, 0.72 nM for murine sEH, and 5 nM for HDAC6. This compound demonstrates notable analgesic and anti-inflammatory properties, making it a valuable tool for research into pain management and inflammatory disorders. The ability to simultaneously target these two enzymes provides insights into their roles in various biological processes. -
sEH/HDAC6 Inhibitor
sEH/HDAC6-IN-2 is a potent dual inhibitor targeting soluble epoxide hydrolase (sEH) and histone deacetylase 6 (HDAC6), demonstrating IC50 values of 0.9 nM for human sEH, 46.8 nM for mouse sEH, and 8 nM for HDAC6. This compound is significant for investigating inflammatory pain mechanisms and related biological pathways, potentially aiding in the development of novel analgesics. Its dual activity positions it as a valuable tool in research focused on neuroinflammation and pain management. -
HO-1 Inducer
HPO-DAEE (4-Hydroperoxy-2-decenoic acid ethyl ester) acts as an inducer of heme oxygenase-1 (HO-1) through the activation of the Nrf2-antioxidant response element (ARE) signaling pathway. This compound promotes the upregulation of various antioxidant genes, providing protective effects against oxidative stress. Additionally, HPO-DAEE exhibits histone deacetylase inhibition, leading to increased expression of extracellular superoxide dismutase via histone acetylation. It has demonstrated efficacy in mitigating cell death induced by 6-hydroxydopamine through the activation of both the Nrf2-ARE and eIF2α-ATF4 pathways, making it a valuable tool for research in oxidative stress-related studies. -
HDAC/PDE5 Inhibitor
CM-414 is a potent dual inhibitor of phosphodiesterase 5 (PDE5) and histone deacetylases (HDACs), exhibiting IC50 values of 60 nM for PDE5 and ranging from 91 nM to 490 nM for various HDAC isoforms, including HDAC6 and HDAC1. This compound effectively reduces levels of amyloid-beta (Aβ) and phosphorylated tau (pTau) in Tg2576 mouse models, making it a valuable tool for Alzheimer's disease research. Its ability to penetrate the blood-brain barrier enhances its potential for studying neurodegenerative disorders and therapeutic interventions. -
Dual HDAC/HSP90 Inhibitor
HDAC/HSP90-IN-2 is a dual inhibitor of histone deacetylases (HDAC) and heat shock protein 90 (HSP90), exhibiting an IC50 of 360 nM for HDAC and 77 nM for HSP90α. This compound effectively induces HSP70 expression, downregulates client proteins associated with HSP90, and enhances the acetylation of α-tubulin and histone H3 in cancer cells. Additionally, HDAC/HSP90-IN-2 reduces PD-L1 expression in H1975 cells treated with IFN-γ. Its applications are particularly relevant in cancer research, including studies focused on lung and colon cancer. -
HDAC/Hsp90 Inhibitor
HDAC/HSP90-IN-3 is a potent dual inhibitor targeting fungal Hsp90 and histone deacetylases (HDAC) with IC50 values of 0.83 μM and 0.91 μM, respectively. This compound demonstrates significant antifungal activity against azole-resistant Candida albicans. Additionally, HDAC/HSP90-IN-3 effectively suppresses key virulence factors and down-regulates drug-resistant genes such as ERG11 and CDR1, making it valuable for research in antifungal resistance and pathogenicity. -
HDAC6/HSP90 Inhibitor
HDAC6/HSP90-IN-1 is a potent dual inhibitor targeting both HDAC6 and HSP90, demonstrating IC50 values of 4.3 nM and 46.8 nM, respectively. This compound effectively down-regulates PD-L1 expression in INF-γ treated H1975 lung cancer cells, contributing to its potential in cancer therapy. Additionally, HDAC6/HSP90-IN-1 has shown promising efficacy in inhibiting tumor growth in human H1975 xenograft mice models, making it a valuable tool for cancer research. -
HDAC/PDE5 Inhibitor
CM-545 is a dual inhibitor targeting both histone deacetylases (HDACs) and phosphodiesterase 5 (PDE5). With pIC50 values of 7.47 for PDE5, 6.65 for HDAC1, 6.14 for HDAC2, 6.55 for HDAC3, and 6.84 for HDAC6, CM-545 demonstrates potent inhibitory activity. This compound has applications in cancer research and therapeutic interventions related to neurodegenerative diseases and cardiovascular conditions, owing to its modulation of histone acetylation and cyclic nucleotide signaling pathways. -
IDO Inhibitor
IDO1 and HDAC1 Inhibitor (Compound 10) is a dual-target inhibitor that effectively inhibits indoleamine 2,3-dioxygenase 1 (IDO1) and histone deacetylase 1 (HDAC1) with IC50 values of 69.0 nM and 66.5 nM, respectively. This compound demonstrates significant biological activity in modulating immune responses and epigenetic regulation. It is suitable for use in cancer research, immunotherapy studies, and investigations into the mechanistic roles of IDO1 and HDAC1 in various biological processes. -
MAO A/HDAC Inhibitor
MAO A/HDAC-IN-1 is a dual inhibitor targeting monoamine oxidase A (MAO A) and histone deacetylases (HDAC). This compound exhibits significant biological activity in glioma research, facilitating studies on tumor biology and epigenetic modifications. Additionally, MAO A/HDAC-IN-1 features an alkyne group that enables copper-catalyzed azide-alkyne cycloaddition (CuAAc), making it a valuable tool for click chemistry applications in investigating cellular processes. -
CYP17A1/HDAC6 Inhibitor
CYP17A1/HDAC6-IN-1 is a dual inhibitor targeting both CYP17A1 and HDAC6, exhibiting IC50 values of 0.284 μM and 0.6015 μM, respectively. This compound demonstrates significant anti-tumor activity, making it a valuable tool for research in cancer biology. Its ability to simultaneously inhibit these targets suggests potential applications in therapeutic strategies against malignancies driven by steroidogenesis and histone deacetylation. -
LSD1/HDAC6/MAO-A Inhibitor
LSD1/HDAC6-IN-2 is a potent inhibitor targeting LSD1, HDAC6, and MAO-A, with IC50 values of 5 nM, 11 nM, and 5 nM, respectively. It demonstrates significant inhibitory effects on the growth of multiple myeloma cell lines, including MM.1S, MM.1R, and RPMI-8226. This compound is suitable for research applications focused on acute myeloid leukemia and lymphoma, providing insights into potential therapeutic mechanisms. -
HDAC6/MAO-A/LSD1 Inhibitor
HDAC6-IN-3 is a potent inhibitor of histone deacetylase 6 (HDAC6), with an IC50 ranging from 0.02 to 1.54 μM for various HDAC isoforms, including HDAC1, HDAC2, HDAC3, and HDAC8. Additionally, it exhibits significant inhibitory activity against monoamine oxidase A (MAO-A) with an IC50 of 0.79 μM and lysine-specific demethylase 1 (LSD1). This compound serves as a valuable tool for research applications in cancer biology and epigenetics and is equipped with an alkyne functionality, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc). -
EZH2/HSP90 Inhibitor
EZH2/HSP90-IN-29 is a dual inhibitor targeting both EZH2 and HSP90, exhibiting IC50 values of 6.29 nM for EZH2 and 60.1 nM for HSP90. This compound enhances the expression of apoptosis and necrosis-related genes, induces M-phase cell cycle arrest, and disrupts the reactive oxygen species catabolism pathway. Additionally, EZH2/HSP90-IN-29 has the capability to cross the blood-brain barrier, making it a valuable tool for research in cancer biology and neurodegenerative diseases. -
Ferroptosis Activator
Ammonium iron(III) citrate serves as a ferroptosis activator through the induction of intracellular iron overload. By increasing cellular iron levels, it promotes oxidative stress and contributes to ferroptotic cell death. This compound is valuable for research involving cellular iron metabolism, oxidative stress studies, and investigations into ferroptosis-related pathways. Additionally, it may enhance protein production, making it relevant for applications in biochemical assays and cellular biology research. -
Ferroptosis Inhibitor
1(R)-(Trifluoromethyl)oleyl alcohol is a trifluoromethyl alcohol derivative of oleic acid that functions as a ferroptosis inhibitor. This compound effectively attenuates ferroptosis induced by Erastin and mitigates lipid peroxidation in human myoblasts with frataxin (FXN) siRNA knockdown. At a concentration of 40 μM, it enhances cell survival to 95% in models of Friedreich ataxia where cell death is largely driven by iron accumulation and glutathione depletion. This makes 1(R)-(Trifluoromethyl)oleyl alcohol a valuable reagent for studying ferroptosis and its related pathways in neurodegenerative diseases. -
Ferroptosis Inhibitor
Ferroptosis-IN-3 is a potent ferroptosis inhibitor targeting the ferroptotic cell death pathway. It effectively inhibits RSL3-induced ferroptosis in HT-1080 cells with an EC50 of 8.6 nM. Additionally, Ferroptosis-IN-3 demonstrates strong free radical scavenging properties, with EC50 values of 3.94 μM for DPPH and 6.3 μM for ABTS, and reduces lipid peroxidation. This compound is ideal for research focused on oxidative stress and cell death mechanisms. -
Glyceraldehyde Derivative
TOFA-Plasmalogen is a glyceraldehyde derivative that induces ferroptosis through the promotion of lipid peroxidation on cellular membranes. This compound exhibits cytotoxic effects with an IC50 of 32.87 μM. TOFA-Plasmalogen is valuable for research applications focused on understanding the mechanisms of cell death and oxidative stress-related disorders. -
15LOX-2 Inhibitor
FerroLOXIN-1 is a potent inhibitor of the enzyme 15-lipoxygenase-2 (15LOX-2) that effectively reduces the production of pro-ferroptotic lipid species, specifically HOO-ETE-PE. This compound has demonstrated protective effects against RSL3-induced ferroptosis, making it a valuable tool in studying ferroptotic pathways. The selective interaction of FerroLOXIN-1 with the active site residues Y154, N155, and W158 of 15LOX-2 underscores its targeted mechanism of action, positioning it as a valuable reagent for research into lipid metabolism and ferroptosis. -
Ferroptosis Inhibitor
Ferroptosis Inducer-6 is a potent inducer of ferroptosis, primarily functioning through the generation of reactive oxygen species (ROS) and the induction of oxidative stress and mitochondrial damage. This compound exhibits anti-tumor activity and serves as a valuable tool for research in type I and II photodynamic therapy. Its ability to trigger ferroptotic cell death makes it significant for studies focused on cancer treatment and exploring the mechanisms of cell death pathways. -
TrxR1 Inhibitor
CS47 is a reversible inhibitor of Thioredoxin reductase 1 (TrxR1). It activates stress-responsive pathways involving glutathione (GSH) and iron regulation, leading to GSH depletion, heightened heme oxygenase-1 (HO-1) expression, and intracellular iron overload, ultimately inducing ferroptosis in KRAS-independent lung cancer models. CS47 demonstrates significant anticancer activity while exhibiting low cytotoxicity towards normal lung fibroblasts, making it a valuable tool for studying cancer mechanisms and therapeutic strategies. -
Ferroptosis Inducer
Lepadin E is a potent ferroptosis inducer that activates cell death through the classical p53-SLC7A11-GPX4 pathway. By promoting p53 expression and downregulating SLC7A11 and GPX4, Lepadin E enhances reactive oxygen species (ROS) and lipid peroxide production while increasing ACSL4 expression. This mechanism underlies its significant antitumor efficacy, making Lepadin E a valuable tool for studying ferroptosis in cancer research. -
Ferroptosis Inhibitor
Ferroptosis-IN-11 is a potent ferroptosis inhibitor targeting the pathways involved in iron-mediated cell death. It effectively inhibits Erastin-induced ferroptosis in HT-1080 human fibroblasts, demonstrating an EC50 of 36 nM. This compound is valuable for research into cardiovascular diseases and neurodegenerative disorders, providing insights into the mechanisms of ferroptosis and potential therapeutic strategies. -
Ferroptosis/MAO-B Inhibitor
MAO-B-IN-45 is a selective inhibitor of MAO-B with an IC50 of 87.47 nM, demonstrating over 229-fold selectivity for MAO-B compared to MAO-A. This compound exhibits significant antiferroptosis activity by modulating the iron metabolic pathway and the glutathione peroxidase 4 (GPX4) axis in vitro. Research indicates that MAO-B-IN-45 enhances cognitive and behavioral functions in 3×Tg (APP/Tau/Ps1) Alzheimer's disease mouse models, while also reducing levels of ferritin heavy chain 1 (FTH1), amyloid precursor protein (APP), and phosphorylated Tau (p-Tau) in the brain. -
Ferroptosis/Apoptosis Inducer
Lepadin H is a potent ferroptosis and apoptosis inducer, demonstrating significant in vitro cytotoxicity and in vivo antitumor efficacy against cancer cells. This compound functions by decreasing the levels of GPX4 and SLC7A11, while enhancing p53 and ACSL4 expression. Lepadin H promotes the generation of lipid hydroperoxides and increases reactive oxygen species (ROS), leading to a reduction in cellular glutathione (GSH) levels and lipid peroxidation. Additionally, it causes G2/M phase cell cycle arrest and inhibits the clonogenic growth and migration of melanoma cells, making it a valuable tool for cancer research. -
Ferroptosis Inducer
AX-53802 is a potent ferroptosis inducer that targets glutathione peroxidase 4 (GPX4) with an IC50 value of 0.34 µM. This compound covalently binds to GPX4, facilitating membrane translocation and subsequent triggering of ferroptotic cell death. In combination with FAK/Src inhibitors, AX-53802 enhances the induction of cell death, making it a valuable tool for cancer research and studies involving ferroptosis mechanisms. -
Ferroptosis Inducer
Ferroptosis inducer-7 selectively induces ferroptosis via the inositol 1,4,5-trisphosphate receptor (IP3R) and calcium release-activated calcium channel protein (ORAI). This compound demonstrates significant biological activity in alleviating symptoms of anemia, suppressing activation of bone marrow cytotoxic T lymphocytes (CTLs), and enhancing hematopoietic function in cases of immune-mediated bone marrow failure. Ferroptosis inducer-7 is valuable for research applications focused on aplastic anemia and related hematological conditions. -
Ferroptosis Inhibitor
Ferrostatin-1 diyne is a potent ferroptosis inhibitor that selectively targets the ferroptotic pathway. This compound is known to accumulate in lysosomes, mitochondria, and the endoplasmic reticulum of cells. Notably, its inhibition of ferroptosis occurs independently of lysosomal and mitochondrial activity, making it a valuable tool for studying ferroptosis-related mechanisms and evaluating therapeutic strategies in various research applications. -
Ferroptosis Inducer
Anticancer agent 147 is a ferroptosis inducer that promotes intracellular accumulation of Fe2+, reactive oxygen species (ROS), and malondialdehyde (MDA). This compound enhances endoplasmic reticulum (ER) stress and upregulates the expression of activating transcription factor ATF3. Anticancer agent 147 exhibits significant anti-liver cancer effects in both in vitro and in vivo models, making it a valuable tool for research in cancer therapy and cell death mechanisms. -
Ferroptosis Inhibitor
RC574 is a novel ferroptosis inhibitor that protects mouse hippocampal cells and primary cortical neurons from glutamate-induced oxidative cell death. It enhances levels and activity of glutathione peroxidase 1 (GPx1), vital for cellular antioxidant defense. This compound is valuable for research into neuroprotection and the mechanisms underlying ferroptosis in neurodegenerative diseases. -
HMG-CoA Reductase Inhibitor
Cerivastatin is a highly potent HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. This synthetic lipid-lowering agent effectively reduces low-density lipoprotein cholesterol levels. In addition to its lipid-modulating effects, Cerivastatin has exhibited inhibitory effects on the proliferation and invasiveness of MDA-MB-231 breast cancer cells, primarily through the inhibition of RhoA signaling, indicating potential applications in cancer research. -
Apoptosis/Ferroptosis Inducer
GIC-20 is a dual inducer of apoptosis and ferroptosis, acting on key cellular pathways involved in programmed cell death. This compound demonstrates significant antitumor efficacy, particularly against fibrosarcoma. GIC-20 is valuable for research applications aimed at exploring mechanisms of cell death and potential therapeutic strategies in cancer biology.
